- Home
- ATRA vs UG Comparison
ATRA vs UG Comparison
Compare ATRA & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- UG
- Stock Information
- Founded
- ATRA 2012
- UG 1942
- Country
- ATRA United States
- UG United States
- Employees
- ATRA N/A
- UG N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- UG Package Goods/Cosmetics
- Sector
- ATRA Health Care
- UG Consumer Discretionary
- Exchange
- ATRA Nasdaq
- UG Nasdaq
- Market Cap
- ATRA 40.1M
- UG 36.9M
- IPO Year
- ATRA 2014
- UG N/A
- Fundamental
- Price
- ATRA $7.94
- UG $8.13
- Analyst Decision
- ATRA Buy
- UG
- Analyst Count
- ATRA 5
- UG 0
- Target Price
- ATRA $17.75
- UG N/A
- AVG Volume (30 Days)
- ATRA 61.5K
- UG 3.8K
- Earning Date
- ATRA 08-11-2025
- UG 08-08-2025
- Dividend Yield
- ATRA N/A
- UG 8.56%
- EPS Growth
- ATRA N/A
- UG 4.93
- EPS
- ATRA N/A
- UG 0.63
- Revenue
- ATRA $199,732,000.00
- UG $11,408,154.00
- Revenue This Year
- ATRA N/A
- UG N/A
- Revenue Next Year
- ATRA N/A
- UG N/A
- P/E Ratio
- ATRA N/A
- UG $13.02
- Revenue Growth
- ATRA 475.53
- UG N/A
- 52 Week Low
- ATRA $5.01
- UG $7.73
- 52 Week High
- ATRA $18.71
- UG $16.25
- Technical
- Relative Strength Index (RSI)
- ATRA 48.77
- UG 46.44
- Support Level
- ATRA $7.74
- UG $8.12
- Resistance Level
- ATRA $9.00
- UG $8.50
- Average True Range (ATR)
- ATRA 0.54
- UG 0.17
- MACD
- ATRA -0.12
- UG -0.00
- Stochastic Oscillator
- ATRA 19.79
- UG 26.09
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About UG United-Guardian Inc.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.